Varenicline does not increase serum BDNF levels in patients with nicotine dependence

Human Psychopharmacology

Volumn 25, Issue 3, 2010, Pages 276-279

  Umene Nakano, Wakako ^a   Yoshimura, Reiji ^a   Yoshii, Chiharu ^b   Hoshuyama, Tsutomu ^b,c   Hayashi, Kenji ^a   Hori, Hikaru ^a   Katsuki, Asuka ^a   Ikenouchi Sugita, Atsuko ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c Ushibuka City Hospital   (Japan)

Author keywords

Addiction; BDNF; Nicotine; Smoking cessation; Varenicline

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CARBON MONOXIDE; VARENICLINE; BENZAZEPINE DERIVATIVE; QUINOXALINE DERIVATIVE;

ABSTINENCE; ARTICLE; BLOOD LEVEL; BREATH ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; HUMAN; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; ADULT; AGED; BLOOD; COMPARATIVE STUDY; FEMALE; MALE; MIDDLE AGED; PROCEDURES; PSYCHOLOGY; TOBACCO USE DISORDER;

ADULT; AGED; BENZAZEPINES; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINOXALINES; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 77950881741     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1113     Document Type: Article

References (33)

1. Bhang SY, Choi SW, Ahn JH. 2010. Changes in plasma brain-derived neurotrophic factor levels in smokers after smoking cessation. Neurosci Lett 468: 7-11.
2. Breslau N, Johnson EO, Hiripi E, Kessler R. 2001. Nicotine dependence in the United States: prevalence, trends, and smoking persistence. Arch Gen Psychiatry 58: 810-816. (Pubitemid 32979297)
3. Chen W-JA, Edwards RB, Romero RD, Parnell SE, Monk RJ. 2003. Longterm nicotine exposure reduces Purkinje cell number in the adult rat cerebellar vermis. Neurotoxicol Teratol 25: 329-334. (Pubitemid 36579183)
4. Durman RS, Heninger GR, Nestler EJ. 1997. A molecular and cellular theory of depression. Arch Gen Psychiatry 54: 597-606.
5. Figurov A, Pozzo-Miller LD, Olafsson P,Wang T, Lu B. 1996. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature 381: 706-709. (Pubitemid 26196571)
6. Gonzales D, Rennard SI, Nides M, et al. 2006. Varenicline Phase 3 Study Group, Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296: 47-55.
7. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. 1991. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict 86: 1119-1127.
8. Hyman C, Hofer M, Barde YA, et al. 1991. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350: 230-232. (Pubitemid 21912205)
9. Joe KH, Kim YK, Kim TS, et al. 2007. Decreased plasma brain-derived neurotrophic factor levels in patients with alcohol dependence. Alcoholism Clin Exp Res 31: 1833-1838. (Pubitemid 47609644)
10. Jorenby DE, Hays JT, Rigotti NA, et al. 2006. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296: 56-63.
11. Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Bertschy G. 2005. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 57: 1068-1072. (Pubitemid 40613035)
12. Karege F, Schwald M, Cisse M. 2002. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 328: 261-264. (Pubitemid 34876661)
13. Kawakami N, Takatsuka N, Inaba S, Shimizu H. 1999. Development of a screening questionnaire for tobacco/nicotine dependence according to ICD-10, DSM-III-R, DSM-IV. Addict Behav 24: 155-166. (Pubitemid 29147114)
14. Kim TS, Kim DJ, Lee H, Kim YK. 2007. Increased plasma brain-derived neurotrophic factor levels in chronicsmokers following unaidedsmoking cessation. Neurosci Lett 423: 53-57. (Pubitemid 47176776)
15. Kim DJ, Roh S, Kim Y, et al. 2005. High concentration of plasma brainderived neurotrophic factor in methamphetamine users. Neurosci Lett 388: 112-115. (Pubitemid 41206742)
16. Lang UE, Hellweg R, Seifert F, Schubert F, Gallinat J. 2007. Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integrity. Biol Psychiatry 62: 530-535. (Pubitemid 47284037)
17. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. 2006. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367: 1747-1757. (Pubitemid 43767064)
18. Matsushita S, Kimura M, Miyakawa T, et al. 2004. Association study of brain-derived neurotrophic factor gene polymorphism and alcoholism. Alcohol Clin Exp Res 28: 1609-1612. (Pubitemid 39551819)
19. Matsuzaki H, Namikawa K, Kiyama H, Mori N, Sato K. 2004. Brainderived neurotrophic factor rescues neuronal death induced by methamphetamine. Biol Psychiatry 55: 52-60. (Pubitemid 38045433)
20. Miyamoto K, Yoshimura R, Ueda N, et al. 2007. Effects of acute paroxetine treatment on the consumption of cigarette smoking and caffeine in depressed patients. Hum Psychopharmacol 22: 483-490. (Pubitemid 47611304)
21. Montag C, Basten U, Stelzel C, Fiebach CJ, Reuter M. 2008. The BDNF Val66Met polymorphism and smoking. Neurosci Lett 442: 30-33.
22. Nides M, Oncken C, Gonzales D, et al. 2006. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist. results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 166: 1561-1568. (Pubitemid 44232363)
23. PanW, BanksWA, Fasold MB, Bluth J, Kastin AJ. 1998. Transport of brainderived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37: 1553-1561. (Pubitemid 28550429)
24. Pontieri FE, Tanda G, Orzi F, Di Chiara G. 1996. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382: 255-257. (Pubitemid 26251360)
25. Schneider NG, Cortner C, Gould JL, Koury MA, Olmstead RE. 2008. Comparison of craving and withdrawal among four combination nicotine treatment. Hum Psychopharmacol 23: 513-517.
26. Sheehan DV, Lecrubier Y, Sheehan KH, et al. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59: 22-33.
27. Shoval G, Weizman A. 2005. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol 15: 319-329.
28. Spina MB, Squinto SP, Miller J, Lindsay RM, Hyman C. 1992. Brainderived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J Neurochem 59: 99-106.
29. Tapper AR, McKinney SL, Nashmi R, et al. 2004. Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science 306: 1029-1032.
30. Umene-Nakano W, Yoshimura R, Ikenouchi-Sugita A, et al. 2009. Serum levels of brain-derived neurotrophic factor in comorbidity of depression and alcohol dependence. Hum Psychopharmacol 24: 409-413.
31. Wu D. 2005. Neuroprotection in experimental stroke with targeted neurotrophins. NeuroRx 2: 120-128.
32. Yeom M, Shim I, Lee HJ, et al. Proteomic analysis of nicotineassociated protein expression in the striatum of repeated nicotine-treated rats. Biochem Biophys Res Commun 326: 321-328.
33. Yoshimura R, Umene-Nakano W, Ueda N, et al. 2008. Addition of risperidone to sertraline improves sertraline-resistant refractory depresssion without influencing plasma concentrations of sertraline and desmethylsertraline. Hum Psychopharmacol 23: 707-713.